DAX22.987 +1,9%ESt505.404 +1,4%Top 10 Crypto11,60 +3,6%Dow41.488 +1,7%Nas17.754 +2,6%Bitcoin75.544 -2,2%Euro1,0882 ±0,0%Öl70,65 +0,7%Gold2.987 ±0,0%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 Tesla A1CX3T NVIDIA 918422 RENK RENK73 Steyr Motors A40TC4 HENSOLDT HAG000 Allianz 840400 Amazon 906866 Palantir A2QA4J Volkswagen (VW) vz. 766403 thyssenkrupp 750000 Deutsche Telekom 555750 Apple 865985 BASF BASF11 Novo Nordisk A3EU6F
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Einigung auf Finanzpaket: DAX geht stärker ins Wochenende -- Wall Street höher -- Daimler Truck: Gewinnrückgang -- BMW mit Margeneinbruch -- Energieaktien, Goldpreis, RENK, D-Wave im Fokus
Top News
Aktueller Marktbericht zu Bitcoin & Co. Aktueller Marktbericht zu Bitcoin & Co.
NVIDIA-Aktie im KI-Rausch: Tom Lee hält an langfristigem KI-Aufschwung fest NVIDIA-Aktie im KI-Rausch: Tom Lee hält an langfristigem KI-Aufschwung fest
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

I-MAB (spons. ADRs) Aktie

NeuKaufenVerkaufen
Aktien-Sparplan anlegen
0,7600 EUR +0,0200 EUR +2,70 %
STU
0,8500 USD +0,0130 USD +1,55 %
nachbörslich
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone
Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2PVC6

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS44975P1030

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolIMAB

I-MAB (spons. ADRs) Aktien News

DatumMeistgelesen
PR NewswireI-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member
PR NewswireI-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program
PR NewswireI-Mab to Participate at the Piper Sandler Healthcare Conference
Wer­bungI-MAB (spons. ADRs)-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireI-Mab Reports Third Quarter 2024 Results
PR NewswireI-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer
PR NewswireI-Mab to Release Q3 2024 Financial Results on November 14, 2024
PR NewswireI-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024
PR NewswireI-Mab to Participate at the Truist Securities BioPharma Symposium
PR NewswireI-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024
PR NewswireI-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer
PR NewswireI-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates
PR NewswireI-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
PR NewswireI-Mab to Release 1H 2024 Financial Results on August 28, 2024
PR NewswireI-Mab Appoints U.S. Auditor, PricewaterhouseCoopers LLP (PwC)
PR NewswireI-Mab Announces Leadership Transitions
PR NewswireI-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer
PR NewswireI-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers
PR NewswireI-Mab to Participate at the Jefferies Global Healthcare Conference
PR NewswireI-MAB Filed 2023 Annual Report on Form 20-F
PR NewswireI-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference
PR NewswireI-Mab Announces Closing of the Divestiture of Business Operations in China
PR NewswireI-Mab Reports Full Year 2023 Financial Results and Business Update
PR NewswireI-Mab Signs Agreement to Divest its Assets and Business Operations in China
PR NewswireI-Mab Announces Participation at Jefferies and Piper Conferences in November
PR NewswireFelzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)
PR NewswireI-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023
PR NewswireI-Mab Announces Phase 1 Data of Givastomig at ESMO 2023
PR NewswireI-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503
PR NewswireI-Mab Announces Upcoming Participation at September Conferences
PR NewswireI-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates
PR NewswireI-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023
PR NewswireI-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC
PR NewswireI-Mab Announces the Appointment of Raj Kannan as CEO
PR NewswireI-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023
PR NewswireI-MAB Filed 2022 Annual Report on Form 20-F
PR NewswireI-Mab Announces Poster Presentation of Proprietary CD73 Antibody Uliledlimab at ASCO 2023
PR NewswireI-Mab Announces Positive Outcome in Arbitration Relating to Agreements with Tracon
PR NewswireI-Mab Announces First Patient Dosed in Phase 3 Registrational Study of CD47 Antibody Lemzoparlimab in MDS in China
PR NewswireI-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022
PR NewswireI-Mab to Report Full Year 2022 Financial Results and Provide Corporate Update on March 31, 2023
Wer­bung

I-MAB (spons. ADRs) News

I-MAB (spons. ADRs) News: auf dieser Seite finden Sie alle I-MAB (spons. ADRs) News und Nachrichten zur I-MAB (spons. ADRs) Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch I-MAB (spons. ADRs) News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um I-MAB (spons. ADRs) News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.